<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2106222244
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OCTAGAM 1GM-20ML I.V
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NORMAL HUMAN IMMUNOGLOBULIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1120.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OCTAPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 521]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Faisal Musaed El Seif Saudi Pharmaceutical Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        J06BA02
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Octagam 50 mg/ml is:</strong></p><p>Octagam 50 mg/ml is a human normal immunoglobulin (IgG) solution (i.e. solution of human antibodies) for intravenous administration (i.e. infusion into a vein). Immunoglobulins are normal constituents of the human body and support the immune defence of your body. Octagam 50&nbsp;mg/ml contains all IgG activities which are present in the normal population. Adequate doses of this medicinal product may restore abnormally low IgG levels to the normal range.</p><p>Octagam 50 mg/ml has a broad spectrum of antibodies against various infectious agents.</p><p><strong>&nbsp;</strong></p><p><strong>What Octagam 50 mg/ml is used for:</strong></p><p>Octagam 50 mg/ml is used</p><p>* as replacement therapy in patients who do not have sufficient amounts of own antibodies.</p><p>* in certain inflammatory diseases.</p><p>* to prevent or treat infections after a bone marrow transplantation.</p><p>&nbsp;</p><p>Octagam 50 mg/ml is used as replacement therapy. There are 3 groups of replacement therapy:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with inborn deficiency of antibodies (primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with diseases of the blood that lead to a lack of antibodies and to recurrent infections (Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with congenital AIDS who have repeated bacterial infections</p><p>&nbsp;</p><p>Octagam 50 mg/ml can be used in the following inflammatory diseases:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adults or children who do not have a sufficient number of platelets (idiopathic thrombocytopenic purpura), and who have a high risk of bleeding prior to surgery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a disease that leads to inflammation of various organs (Kawasaki disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a disease that can lead to inflammation of certain parts of the nervous system (Guillain Barr&eacute; syndrome)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1BWhat you need to know before you use Octagam 50 mg/ml</p><p><strong>&nbsp;</strong></p><p><strong>Do not use Octagam 50 mg/ml:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to human immunoglobulin or any of the other ingredients contained in Octagam 50 mg/ml (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a deficiency of immunoglobulin A (IgA deficiency) with anti-IgA antibodies.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Octagam 50 mg/ml.</p><p>In the case of an adverse reaction, either the rate of administration must be reduced or the infusion must be stopped. The treatment of the adverse event required will depend on the nature and severity of the side effect.</p><p>&nbsp;</p><p>U<u>Virus safety</u></p><p>When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; testing of each donation and pools of plasma for signs of virus/infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.</p><p>Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.</p><p>The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.</p><p>The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19.</p><p>Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.</p><p>It is strongly recommended that every time that you receive a dose of Octagam 50 mg/ml the name and batch number of the medicine are recorded in order to maintain a record of the batches used.</p><p>&nbsp;</p><p>U<u>Corn allergy</u></p><p>Octagam 50 mg/ml contains maltose, which is derived from corn. Allergic reactions have been reported in association with infusion of other maltose / corn starch related products. If you have a known corn allergy, you should either avoid using Octagam 50 mg/ml or be closely observed for signs and symptoms of hypersensitivity reactions during the infusion of Octagam 50 mg/ml.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>There are no specific or additional warnings or precautions applicable for children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and Octagam 50 mg/ml</strong></p><p>The infusion line may be flushed before and after administration of Octagam 50 mg/ml with either normal saline or 5% dextrose in water.</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, or if you have received a vaccination in the last three months.</p><p>Octagam 50 mg/ml may impair the effect of live viral vaccines such as measles, rubella, mumps and varicella.</p><p>After administration of this product, an interval of 3 months should elapse before vaccination with live viral vaccines. In the case of measles, this impairment may persist for up to 1 year.</p><p>Inform your doctor that you are taking immunoglobulin when you give a blood sample, as this treatment may affect the results.</p><p>&nbsp;</p><p>U<u>Blood Glucose Testing</u></p><p>Some types of blood glucose testing systems (so called glucometers) falsely interpret the maltose contained in Octagam 50 mg/ml as glucose. This may result in falsely elevated glucose readings <strong>during an infusion and</strong> for a period of about 15 hours after the end of the infusion and, consequently, in the inappropriate administration of insulin, resulting in lifethreatening hypoglycaemia (i.e. a decreased blood sugar level).</p><p>Also, cases of true hypoglycaemia may go untreated if the hypoglycaemic state is masked by falsely elevated glucose readings.</p><p><strong>Accordingly, when administering Octagam 50 mg/ml or other maltose containing products, the measurement of blood glucose must be done with a test-system using a glucose-specific method. </strong><strong>Systems based on the </strong><strong>glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ) or </strong><strong>glucose-dye-oxidoreductase methods should not be used.</strong></p><p>Review carefully the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose containing parenteral products. If any uncertainty exists, please ask your treating physician to determine if the glucose testing system you are using is appropriate for use with maltose containing parenteral products.</p><p><strong>&nbsp;</strong></p><p><strong>Octagam </strong><strong>50 mg/ml with food, drink and alcohol</strong></p><p>No effects have been observed. While using Octagam 50 mg/ml adequate hydration before infusion should be taken into account.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.</p><p>The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Immunoglobulin preparations have been shown to cross the placenta, increasingly during the third trimester. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.</p><p>Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the newborn.</p><p>Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines:</strong></p><p>The ability to drive and operate machines may be impaired by some adverse reactions associated with Octagam 50 mg/ml. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide if you need Octagam 50 mg/ml and at what dose. Octagam 50 mg/ml is administered as an intravenous infusion (infusion into a vein) by healthcare personnel. The dose and dosage regimen is dependent on the indication and may need to be individualised for each patient.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor as soon as possible if you suffer from any of the serious side effects listed below (<strong>all are very rare </strong>and may affect up to 1 in 10,000 people).</p><p>In some cases your doctor may need to interrupt treatment and reduce your dose or stop treatment:</p><p>&nbsp;</p><ul><li><strong>Swelling</strong> <strong>of the face, tongue and windpipe</strong> that can cause great difficulty in breathing</li><li><strong>A sudden allergic reaction</strong> with shortness of breath, rash, wheezing and drop of blood pressure</li><li><strong>Stroke</strong> that may cause weakness and / or loss of sensation down one side of the body</li><li><strong>Heart attack</strong> causing chest pain</li><li><strong>Blood clot </strong>causing pain and swelling of limbs</li><li><strong>Blood clot in lung</strong> causing chest pain and breathlessness</li><li><strong>Severe kidney disorder</strong> that may cause you to not pass urine</li><li><strong>Non-infectious (aseptic) meningitis</strong> causing severe headache and neck stiffness</li></ul><p>&nbsp;</p><p>If you experience any of the symptoms above, contact your doctor as soon as possible.</p><p>&nbsp;</p><p>The following other side effects have also been reported:</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people):</p><ul><li>Hypersensitivity (allergic reaction)</li><li>Headache</li><li>Nausea</li><li>Fever</li><li>Feeling tired</li><li>Skin reactions at injection site</li></ul><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people):</p><ul><li>Eczema</li><li>Back pain</li><li>Chest pain</li><li>Chills</li></ul><p>&nbsp;</p><p><strong>Very rare side effects</strong> (may affect up to 1 in 10,000 people):</p><ul><li>haemolytic anaemia (Destruction of and resulting lack of red blood cells; this side effect may be increased in individuals receiving high doses, that have blood group A, B or AB and / or an underlying inflammatory disease)</li><li>Lack of white blood cells</li><li>Fluid overload</li><li>Too low sodium in blood</li><li>Feeling agitated, anxious, confused or nervous</li><li>Migraine</li><li>Speech disorder</li><li>Loss of consciousness</li><li>Dizziness</li><li>Tingling sensation in skin</li><li>Reduced sense of touch or sensation</li><li>Sensitivity to light</li><li>Involuntary muscle contractions</li><li>Impaired vision</li><li>Angina pectoris</li><li>Palpitations</li><li>Changes in heart beat</li><li>Temporary bluish lips or other parts of skin</li><li>Circulatory collapse or shock</li><li>Changes in blood pressure</li><li>Vein inflammation</li><li>Pale color of the skin</li><li>Cough</li><li>Breathing disorders</li><li>Pulmonary oedema (accumulation of fluid in the lung)</li><li>Bronchospasm (difficulty in breathing or wheezing)</li><li>Respiratory failure</li><li>Lack of oxygen in the blood</li><li>Vomiting, diarrhoea, abdominal pain</li><li>Hives, skin itching</li><li>Redness of skin</li><li>Skin rash</li><li>Peeling of the skin</li><li>Inflammation of the skin</li><li>Hair loss</li><li>Pains in joints or muscles</li><li>Muscle weakness or stiffness</li><li>Strong painful muscle contraction</li><li>Neck pain, pain in legs or arms</li><li>Kidney pain</li><li>Swelling of the skin (oedema)</li><li>Flushing, increased sweating</li><li>Chest discomfort</li><li>Flu-like symptoms</li><li>Feeling cold or hot or generally unwell and weak</li><li>Drowsiness</li><li>Burning sensation</li><li>Abnormalities in blood test reports of liver function</li><li>False readings for blood sugar measurements</li></ul><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p>To report any side effect(s):</p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p><p><strong>The following information is intended for medical or healthcare professionals only:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The product should be brought to room or body temperature before use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should be clear to slightly opalescent and colourless to slightly yellow.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use solutions that are cloudy or have deposits.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filtration of Octagam 50 mg/ml is not required</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product should not be mixed with other medicinal products.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion line may be flushed before and after administration of Octagam 50 mg/ml with either normal saline or 5% dextrose in water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use Octagam 50 mg/ml after the expiry date which is stated on the label and the carton.</p><p>Store below 25&deg;C. Do not freeze. Keep container in the outer carton in order to protect from light.</p><p>Do not use Octagam 50 mg/ml if you notice that the solution is cloudy, has deposits or is coloured intensively.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; &nbsp; &nbsp;</p><p><strong>What Octagam 50 mg/ml contains:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is human normal immunoglobulin 50 mg/ml (at least 95% is immunoglobulin G).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are maltose and water for injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Components used in the packaging of Octagam 50 mg/ml are latexfree.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Octagam 50 mg/ml looks like and contents of the pack:

Octagam 50 mg/ml is a solution for infusion and is available in bottles (1 g/20 ml, 2.5 g/50 ml, 5 g/100 ml, 10 g/200 ml, 25 g/500 ml).



Pack sizes:



        1 g           in                 20 ml

        2.5 g        in                 50 ml

        5 g           in                 100 ml

        10 g         in                 200 ml

        25 g         in                 500 ml

Not all pack sizes may be marketed.

The solution is clear or slightly opalescent, colourless or slightly yellow.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder:</strong></p><p>Octapharma Pharmazeutika Produktionsges.m.b.H.</p><p>Oberlaaer Strasse 235, A-1100 Vienna, Austria</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p>Octapharma Pharmazeutika Produktionsges.m.b.H.</p><p>Oberlaaer Strasse 235, A-1100 Vienna, Austria</p><p><strong>&nbsp;</strong></p><p>Octapharma S.A.S.</p><p>70-72 rue de Mar&egrave;chal Foch, BP 33, F-67380 Lingolsheim, France</p><p>Octapharma AB</p><p>SE-112 75 Stockholm, Sweden</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>This leaflet was last revised in 10/2023</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبيعة عقار أوكتاجام 50ملغم/مل ، ودواعي استخدامه</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طبيعة عقار أوكتاجام </strong>50 ملغم/مل</p><p dir="RTL">يتم تناول عقار أوكتاجام <strong>50ملغم/مل</strong> الذي هو عبارة عن محلول للجلوبيولين المناعي الطبيعي للإنسان (النوع G) يتم الحقن في الوريد (كمحاليل الأجسام المضادة التي يستخدمها الإنسان). الجلوبيولينات المناعية هي مقومات طبيعية للجسم البشري، يتم استخدامها لدعم الدفاع المناعي للجسم. يحتوي أوكتاجام <strong>50ملغم/مل</strong> على منشطات للجلوبيولين المناعي الطبيعي (النوع G) الموجود بالفعل في أجسام البشر الطبيعيين. تناول الجرعات المناسبة من هذا المنتج العلاجي قد يؤدي إلى إعادة مستويات الجلوبيولين المناعي (النوع G) المنخفض إلى مستواه الطبيعي.</p><p dir="RTL">يحتوي أوكتاجام <strong>50ملغم/مل</strong> على مجموعة كبيرة من الأجسام المضادة التي تعمل ضد العديد من العوامل المسببة للعدوى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>دواعي استخدام عقار أوكتاجام 50ملغم/مل</strong></p><p dir="RTL">يتم استخدام عقار أوكتاجام <strong>50ملغم/مل</strong></p><p dir="RTL">* كعلاج بديل للمرضى الذين يعانون من نقص في كميات الأجسام المضادة الذاتية.</p><p dir="RTL">* مع بعض الأمراض الالتهابية</p><p dir="RTL">* للوقاية من العدوى أو للعلاج منها بعد إجراء عمليات زرع نُـقي النخاع العظمي</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم أوكتاجام <strong>50ملغم/مل </strong>كعلاج بديل. هناك ثلاث مجموعات من العلاجات البديلة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بنقص فطري في الأجسام المضادة (المتلازمات الأولية لنقص المناعة: نقص فطري في جلوبيولينات جاما، ونقص جلوبيولينات جاما، والنقص المناعي المتغير الشائع، والنقص المناعي المركب الحاد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يعانون من أمراض الدم التي تؤدي إلى نقص في الأجسام المضادة وتكرار حالات العدوى (ابيضاض الدم الليمفاوي المزمن أو الذي يصاحبه ورم نقوي مع نقص جلوبيولينات جاما الحاد الثانوي وحالات العدوى المتكررة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يعانون من متلازمة نقص المناعة المكتسبة وتكررت لديهم حالات العدوى البكتيرية</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام أوكتاجا<strong>50ملغم/مل</strong> م مع الأمراض الالتهابية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع البالغين أو الأطفال الذين يعانون من نقص في عدد الصفائح الدموية (الفُرْفُرِيَّةُ قَليلَةُ الصُّفَيحاتِ مَجْهولَةُ السَّبَب)، أو الذين يتعرضون لمخاطر كبيرة جراء النزف، أو قبل إجراء عملية جراحية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى الذين يعانون من مرض ما يؤدي إلى التهاب العديد من الأعضاء (مرض كاواساكي)</p><p dir="RTL">مع المرضى الذين يعانون من مرض يمكن أن يتسبب في التهاب أجزاء بعينها في النظام العصبي (متلازمة غيلان باريه</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تستخدم أوكتاجام <strong>50ملغم/مل</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية من الجلوبيولين المناعي البشري أو أي من المكونات التي يتكون منها أوكتاجام <strong>50ملغم/مل </strong>(انظر الجزء 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص في الجلوبيولين المناعي من النوع A مع وجود أجسام مضادة لمستضدات الجلوبيولين المناعي من النوع A.</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">قم بإخبار طبيبك او الصيدلاني &nbsp;قبل استخدام اوكتاجام 50 ملغم/مل<strong> .</strong></p><p dir="RTL">في حال التعرض لأي رد فعل عكسي، أو وجوب تقليل الجرعة التي تتناولها، أو إيقاف الحقن الوريدي. سيتوقف العلاج المطلوب لهذا الحدث العكسي وفقًا لطبيعة العرض الجانبي وشدته.</p><p dir="RTL"><strong><u>السلامة من انتقال الفيروس</u></strong></p><p dir="RTL">عند صناعة الأدوية من دم أو بلازما كائن بشري، تكون هناك مقاييس يتعين الالتزام بها للوقاية من العدوى التي يتم انتقالها إلى المرضى. وهذا يتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختيار الدقيق لمتبرعي الدم والبلازما بحيث يتم التأكد من عدم وجود أي مخاطر من حمل العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار كل عملية تبرع وأحواض البلازما لتفقد أي علامات لفيروس/عدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخطوات التي تدرجها المصانع في عملية معالجة الدم أو البلازما، والتي بإمكانها أن تثبط من عمل الفيروس أو التخلص منه.</p><p dir="RTL">بخلاف هذه المقاييس، عند تناول الأدوية المعدَّة من دم أو بلازما بشرية، لا يمكن استبعاد إمكانية نقل العدوى تمامًا. وينطبق هذا أيضًا على أي فيروسات غير معروفة أو ناشئة، أو أي أنواع أخرى من العدوى.</p><p dir="RTL">تعد المقاييس التي تم تسجيلها ذات فعالية بالنسبة للفيروسات المغلفة، والتي تتضح على سبيل المثال في فيروس نقص المناعة المكتسبة البشري (الإيدز)، وفيروس الالتهاب الكبدي الوبائي B، وفيروس الالتهاب الكبدي الوبائي C.</p><p dir="RTL">قد تكون المقاييس المأخوذة عبارة عن قيمة محدودة مضادة للفيروسات الغير مغلفة، والتي تتضح على سبيل المثال في فيروس الالتهاب الكبدي الوبائي A والفيروس بارفو فيروس B19.</p><p dir="RTL">ربما لا يرتبط الجلوبيولين المناعي في حالات العدوى بفيروس الالتهاب الكبدي الوبائي A أو البايرو فيروس B19 نظرًا لأن الأجسام المضادة الموجودة في هذا المنتج والتي يسير اتجاه عملها ضد هذه الحالات من العدوى تكون أجسامًا وقائية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينصح بشدة بتسجيل الاسم ورقم تشغيلة المنتج في كل مرة يتم فيها تناول جرعة من أوكتاجام <strong>50 ملغم/مل&nbsp; </strong>&nbsp;وذلك للمحافظة على وجود سجل يضم التشغيلات المستخدمة.</p><p dir="RTL">الحساسية للذرة</p><p dir="RTL">يحتوي اوكتاغام<strong>50 ملغم/مل&nbsp; </strong>&nbsp;على المالتوز المشتق من الذرة. تم الإبلاغ عن ردود الفعل التحسسية بالترافق مع تسريب المنتجات الأخرى المتعلقة بنشا المالتوز / الذرة. إذا كانت لديك حساسية معروفة تجاه الذرة يجب عليك إما تجنب استخدام اوكتاغام 50مغ/مل أو أن تخضع للمراقبة المستمرة لعلامات وأعراض تفاعلات فرط الحساسية أثناء التسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا توجد تحذيرات أو محاذير خاصة أو إضافية واجبة التطبيق بالنسبة للأطفال والمراهقين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الادويه الاخرى و اوكتاجام 50 ملغم/مل </strong></p><p dir="RTL">قد يتدفق خط الحقن بغزارة قبل وبعد تناول أوكتاجام <strong>50 ملغم/مل </strong>&nbsp;سواء كان ذلك مع محلول ملحي عادي أو في حال وجود 5% من الدكستروز في الماء.</p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو كنت قد تناولت مؤخرًا أيًا منها، بما في ذلك الأدوية التي يتم الحصول عليها دون وصف طبيب، أو في حال التلقيح خلال الأشهر الثلاث الأخيرة.</p><p dir="RTL">قد يضعف أوكتاجام <strong>50 ملغم/مل &nbsp;</strong>تأثير لقاح الفيروس المضعف والذي يتضح على سبيل المثال في مرض الحصبة، والحصبة الألمانية، وفيروس النُّكاف، والحماق.</p><p dir="RTL">بعد تناول هذا المنتج، يجب أن تمر فترة فاصلة قدرها ثلاثة أشهر قبل التلقيح بلقاح الفيروسات المضعفة. في حال الإصابة بالحصبة، قد يستمر هذا العجز لفترة تصل إلى عام كامل.</p><p dir="RTL">أبلِغ طبيبك بأنك تتناول الجلوبيولين المناعي عند ترك عينة من الدم، وذلك لأن هذا العلاج قد يؤثر على النتائج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>اختبار جلوكوز الدم</u></p><p dir="RTL">بعض أنظمة اختبار جلوكوز الدم (التي يطلق عليها أجهزة قياس نسبة السكر) ترى المالتوز الموجود في أوكتاجام <strong>50 ملغم /مل </strong>&nbsp;على أنه جلوكوز. قد يؤدي هذا إلى ظهور نتائج خاطئة في قراءات الجلوكوز الناتجة <strong>أثناء التقطير </strong>وذلك حتى فترة 15 ساعة بعد <em>الحقن</em> وبناء عليه يترتب تناول جرعة غير مناسبة من الإنسولين؛ الأمر الذي قد يهدد بالإصابة بمرض نقص السكر في الدم (على سبيل المثال: انخفاض مستوى السكر في الدم).</p><p dir="RTL">هذا بالإضافة إلى أن الانخفاض الفعلي في مستوى السكر في الدم قد يصعب الشفاء منه إذا تم تضليل حالة مرض نقص السكر في الدم بقراءات جلوكوز غير صحيحة.</p><p dir="RTL"><strong>وبناء على ذلك، عند تناول أوكتاجام </strong>50 ملغم /مل <strong>أو أي منتجات أخرى تحتوى على المالتوز، يجب أن يتم قياس جلوكوز الدم بنظام اختبار يعتمد على استخدام أداة من شأنها تحديد عنصر الجلوكوز. لا يجب استخدام<em> الأنظمة التي تعتمد على الوسائل النازعة لهيدروجين الجلوكوز </em></strong><strong><em>كالبايرولوكينولين كينون </em></strong><em>و<strong>جلوكوز داي أوكسيدوريدوكتاز.</strong></em></p><p dir="RTL">راجع بدقة معلومات المنتج الخاصة بنظام اختبار الجلوكوز في الدم، بما في ذلك شرائط الاختبار، وذلك من أجل تحديد ما إذا كان النظام مناسبًا للاستخدام عند تناول أي من المنتجات التي يتم حقنها وتحتوي على المالتوز. إذا كان هناك أي شك، فيُرجى مراجعة الطبيب المعالج لتحديد ما إذا كان نطام اختبار الجلوكوز الخاص بك مناسبًا للاستخدام في حال تناول أي منتجات حقن تحتوى على المالتوز أو غير مناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>5</strong><strong> </strong><strong>أوكتاجام </strong><strong>50</strong><strong>م</strong><strong>لغم</strong><strong>/مل مع الطعام والشراب والكحول :</strong></p><p dir="RTL">لم يتم ملاحظة أية تأثيرات. أثناء استخدام ا<strong> </strong><strong>أوكتاجام</strong> 50 مغ/مل يجب الأخذ بعين الاعتبار الحصول على الترطيب (التميّه) الكافي قبل التسريب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بالنسبة للحمل والرضاعة الطبيعية والخصوبة :</strong></p><p dir="RTL">اذا كنتي حامل او مرضع او تعتقدي اتك حامل او تخططي للحمل راجع الطبيب أو الصيدلي للحصول على النصائح اللازمة قبل تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم إجراء اختبارات للتأكد من سلامة هذا المنتج العلاجي على السيدات الحوامل في الاختبارات السريرية الخاضعة للمراقبة، ومن ثم ينبغي تناول هذا العقار بحذر شديد مع السيدات الحوامل والأمهات المرضعات. تنم التجارب السريرية المتعلقة بالجلوبيولين المناعي بأنه من غير المتوقع التعرض لأي آثار ضارة أثناء فترة الحمل على الأم، أو الجنين والأطفال حديثي الولادة.</p><p dir="RTL">يتم إفراز الجلوبيولين المناعي في لبن الأم، الأمر الذي يساهم في نقل الأجسام المضادة الوقائية إلى الأطفال حديثي الولادة.</p><p dir="RTL">الدراسات السريرية لل الجليوبيولين المناعي تقترح انه لايوجد تأثيرات &nbsp;ضارة على الخصوبة يمكن توقعها .</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">القدرة على السياقه والتعامل مع الاجهزة يمكن ان يتاثر ببعض التاثيرات الجانبيه المصاحبة لاستخدام &nbsp;أوكتاجام 50ملغم/مل.</p><p dir="RTL">المرضى الذين يتوقعون حدوث اعراض جانبيه خلال فترة العلاج ,يجب عليهم الانتظار حتى يتم حل&nbsp; الاعراض الجانبية قيل السياقه او التعامل مع الاجهزة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك الخاص ما إذا كنت بحاجة لتناول أوكتاجام <strong>50 ملغم/مل </strong>وكذلك الجرعة اللازمة. يتم تناول عقار أوكتاجام<strong>50 ملغم/مل</strong> من خلال الحقن في الوريد تحت اشراف طبي. يعتمد كل من الجرعة ونظامها على المؤشرات، وقد تختلف حاجة كل مريض للجرعة عن غيره.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك مزيد من الاستفسارات حول استخدام المنتج، فاسأل طبيبك الخاص أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جميع الأدوية، يمكن لهذا الدواء أن يسبب تأثيرات جانبية على الرغم من أنها قد لا تصيب الجميع.</p><p dir="RTL">قم بالاتصال بطبيبك حالما تعاني من أية تأثيرات جانبية خطيرة مدرجة أدناه (جميعها نادرة جداً ويمكن أن تؤثر على 1 من كل 10000 شخص).</p><p dir="RTL">في بعض الحالات&nbsp; قد يحتاج طبيبك أن يقوم بإيقاف العلاج وتقليل الجرعة أو إيقافها نهائياً:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>تورم الوجه واللسان والقصبة الهوائية</strong> الذي يمكن أن يسبب صعوبة كبيرة في التنفس</li><li dir="RTL"><strong>تفاعل تحسسي مفاجئ</strong> مع ضيق التنفس والطفح الجلدي والصفير عند التنفس وضغط الدم</li><li dir="RTL"><strong>السكتة الدماغية</strong> التي قد تسبب ضعف و / أو فقدان الإحساس في جانب واحد من الجسم</li><li dir="RTL"><strong>نوبة قلبية</strong> تسبب ألم في الصدر</li><li dir="RTL"><strong>جلطة دموية</strong> تسبب الألم وتورم الأطراف</li><li dir="RTL"><strong>تجلط الدم في الرئة</strong> مما يسبب ألم في الصدر وضيق في التنفس</li><li dir="RTL"><strong>اضطراب الكلى الحاد</strong> الذي قد يسبب عدم التبول</li><li dir="RTL"><strong>التهاب السحايا غير المعدي</strong> الذي يسبب الصداع الشديد وتصلّب الرقبة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من أي من الأعراض أعلاه، اتصل بطبيبك على الفور.</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية الأخرى التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (يمكن أن تؤثر على 1 من كل 10 أشخاص)</strong></p><ul><li dir="RTL">فرط الحساسية (رد فعل تحسسي)</li><li dir="RTL">صداع</li><li dir="RTL">غثيان</li><li dir="RTL">حمى</li><li dir="RTL">الشعور بالتعب</li><li dir="RTL">تفاعلات في الجلد في موضع الحقن</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (يمكن أن تؤثر على 1 من كل 100 أشخاص)</strong></p><ul><li dir="RTL">أكزيما</li><li dir="RTL">ألم الظهر</li><li dir="RTL">ألم الصدر</li><li dir="RTL">القشعريرة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية النادرة جداً (يمكن أن تؤثر على 1 من كل 10000 أشخاص)</strong></p><ul><li dir="RTL">فقر الدم الانحلالي (تدمير خلايا الدم الحمراء والنتائج المترتبة عليها)؛ وقد يزداد هذا الأثر الجانبي لدى الأفراد الذين يتلقون جرعات عالية ومن مجموعة دم A أو B أو AB و / أو يعانون من مرض التهابي مزمن</li><li dir="RTL">عدم وجود خلايا الدم البيضاء</li><li dir="RTL">زيادة السوائل</li><li dir="RTL">الانخفاض الحاد في الصوديوم في الدم</li><li dir="RTL">الشعور بالقلق أو التشوش أو العصبية</li><li dir="RTL">صداع نصفي</li><li dir="RTL">اضطراب الكلام</li><li dir="RTL">فقدان الوعي</li><li dir="RTL">دوار</li><li dir="RTL">الإحساس بالوخز في الجلد</li><li dir="RTL">تقليل الإحساس باللمس أو الإحساس</li><li dir="RTL">الحساسية للضوء</li><li dir="RTL">تقلصات العضلات اللاإرادية</li><li dir="RTL">ضعف البصر</li><li dir="RTL">الذبحة الصدرية</li><li dir="RTL">الخفقان</li><li dir="RTL">التغيرات في ضربات القلب</li><li dir="RTL">ازرقاق الشفاه أو أجزاء أخرى من الجلد</li><li dir="RTL">انهيار في الدورة الدموية أو صدمة</li><li dir="RTL">التغيرات في ضغط الدم</li><li dir="RTL">التهاب الأوردة</li><li dir="RTL">شحوب لون الجلد</li><li dir="RTL">السعال</li><li dir="RTL">اضطرابات التنفس</li><li dir="RTL">الوذمة الرئوية (تراكم السوائل في الرئة)</li><li dir="RTL">التشنج القصبي (صعوبة في التنفس)</li><li dir="RTL">توقف التنفس</li><li dir="RTL">نقص الأكسجين في الدم</li><li dir="RTL">القيء والإسهال وآلام البطن</li><li dir="RTL">الطفح وحكة في الجلد</li><li dir="RTL">احمرار الجلد</li><li dir="RTL">الطفح الجلدي</li><li dir="RTL">تقشير الجلد</li><li dir="RTL">التهاب الجلد</li><li dir="RTL">تساقط الشعر</li><li dir="RTL">آلام المفاصل أو العضلات</li><li dir="RTL">ضعف العضلات أو تصلبها</li><li dir="RTL">تقلص العضلات المؤلم</li><li dir="RTL">آلام الرقبة، آلام في الساقين أو الذراعين</li><li dir="RTL">آلام الكلى</li><li dir="RTL">تورم في الجلد (وذمة)</li><li dir="RTL">الهبات الساخنة، زيادة التعرق</li><li dir="RTL">الشعور بعدم الراحة في الصدر</li><li dir="RTL">أعراض تشبه اعراض الانفلونزا</li><li dir="RTL">الشعور بالبرودة أو الحرارة أو الضعف بشكل عام</li><li dir="RTL">النعاس</li><li dir="RTL">الشعور بالحرقة</li><li dir="RTL">اضطرابات في نتائج فحوصات الدم ووظائف الكبد</li><li dir="RTL">اضطرابات في قياسات السكر في الدم</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">في حال أصبت بأي من الأعراض الجانبية تحدث إلى طبيبك أو الصيدلاني. يشمل هذا أية تأثيرات جانبية محتملة وغير مدرجة في هذه النشرة. يمكنك أيضاً الإبلاغ عن الأعراض الجانبية مباشرة. بالإبلاغ عن الأعراض الجانبية يمكنك المساعدة في تزويد المزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>فاكس:&nbsp; ٧٦٦٢-٢٠٥-١١-٩٦٦+</strong></p><p dir="RTL"><strong>هاتف:&nbsp; ٨٢٢٢-٢٠٣-١١-٩٦٦+</strong></p><p dir="RTL"><strong>تحويلة: ٢٣١٧ &ndash; ٢٣٥٦ &ndash; 2353- 2354- 2334- 2340</strong></p><p dir="RTL"><strong>الهاتف المجاني: ٨٠٠٢٤٩٠٠٠٠</strong></p><p dir="RTL"><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL"><strong>الموقع الإلكتروني: </strong><strong>www.sfda.gov.sa/npc</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المعلومات التالية مخصصة للمتخصصين في المجال الطبي أو الرعاية الصحية فقط:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إيصال المنتج إلى درجة حرارة الغرفة أو الجسم قبل الاستخدام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻳﺠﺐ أن ﻳﻜﻮن اﻟمحلول نقياً أو معتماً قليلاً ولكن بلا لون إﻟﻰ مصفرّ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻻ ﺗﺴﺘﺨﺪم المحلول الذي يحتوي على رواﺳﺐ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يشترط تصفية اوكتاغام&nbsp; <strong>50 ملغم/مل&nbsp; </strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخلص من أي منتج أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا يتم خلط هذا المنتج الطبي مع منتجات طبية أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن شطف أنبوب التسريب قبل وبعد إعطاء اوكتاغام 50 مغ/مل إما بمحلول ملحي طبيعي أو 5% من الدكستروز في الماء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يجب الاحتفاظ به بعيدًا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم أوكتاجام<strong>50 ملغم/مل</strong>&nbsp; بعد انتهاء مدة صلاحيته المدونة على ملصق المنتج وعلبته الكرتونية.</p><p dir="RTL">يتم حفظه &nbsp;عند درجة حرارة &nbsp;اقل من 25 درجة &nbsp;مئوية. احتفظ بوجود حاوية العقار داخل علبته الكرتونية الخارجية لحمايته من الضوء. لا تقم بتجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم أوكتاجام <strong>50 ملغم/مل </strong>إذا لاحظت تعكر المحلول، أو انتبهت لاحتوائه على رواسب، أو تغير لونه بشكل جذري.</p><p dir="RTL">لا ينبغي التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنزلية. استفسر من الصيدلي عن كيفية التخلص من الأدوية إذا لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; &nbsp; &nbsp;</p><p dir="RTL"><strong>ما يحتوي عليه عقار أوكتاجام 50 ملغم/مل </strong>%<strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي الجلوبيولين المناعي الطبيعي للإنسان <strong>50 ملغم/مل </strong><strong>&nbsp;</strong>(على الأقل نسبة 95% من العقار تتمثل في الجلوبيولين المناعي G).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بينما تتمثل المكونات الأخرى في المالتوز والمياه اللازمة للحُقَن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد المستخدمة في تغليف&nbsp; أوكتاجام 50 ملغم/مل خاليه من الاتكس<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الهيئة التي يكون عليها عقار أوكتاجام &nbsp;50 ملغم/مل</strong> <strong>بالإضافة إلى محتويات العبوة:</strong></p><p dir="RTL"><strong>أوكتاجام 50 ملغم/مل</strong> عبارة عن محلول تقطير، متوفر في قارورة (1جم/20 ملم , 2.5 جم /50 ملم , 5 جم/100 ملم، 10جم/200 ملم ,25 جم /500 ملم ).</p><p dir="RTL">يكون المحلول نقيًا، أو غميمًا بعض الشيء، بلا أي لون أو يميل إلى الصفرة.</p><p dir="RTL"><strong>قد</strong> لا تتوفر بعض أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>مالك رخصة التسويق</u><br /><strong>شركة </strong>Octapharma Pharmazeutika Produktionsges.m.b.H<strong>. </strong></p><p dir="RTL">Oberlaaer Strasse 235, A-1100 Vienna, Austria</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شركات التصنيع:</strong></p><p dir="RTL">Octapharma Pharmazeutika Produktionsges.m.b.H<strong>. </strong></p><p dir="RTL">Oberlaaer Strasse 235, A-1100 Vienna, Austria</p><p dir="RTL">&nbsp;</p><p dir="RTL">Octapharma S.A.S.</p><p dir="RTL">70-72 rue de Mar&egrave;chal Foch, BP 33, F-67380 Lingolsheim, France</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">Octapharma AB</p><p dir="RTL">SE-112 75 Stockholm, Sweden</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OCTAGAM®
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	Active ingredients Human normal immunoglobulin (IVIg)
2.2	Quantitative composition:
1 ml solution contains:
Protein	50 mg
of which  95% is human Immunoglobulin G
IgA	 0.2 mg
Distribution of IgG subclasses:
IgG1	ca. 60 %
IgG2	ca. 32 %
IgG3	ca.   7 %
IgG4	ca.   1 %
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Replacement therapy in adults, and children and adolescents (0-18 years) in:</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary immunodeficiency syndromes with impaired antibody production (see Section</p><p>4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital AIDS with recurrent bacterial infections.</p><p><strong><em>Immunomodulation in adults, and children and adolescents (0-18 years) in:</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain Barr&eacute; syndrome</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kawasaki disease</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.</p><p>Posology</p><p>The dose and dosage regimen is dependant on the indication.</p><p>In replacement therapy the dosage may need to be individualised for each patient dependant on the pharmacokinetic and clinical response.</p><p>The following dosage regimens are given as a guideline.</p><p><u>Replacement therapy in primary immunodeficiency syndromes:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 - 6 g/l. Three to six months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 0.4 - 0.8 g/kg given once followed by at least 0.2 g/kg every three to four weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose required to achieve a trough level of 5 - 6 g/l is of the order of 0.2 0.8 g/kg/month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dosage interval, when steady state has been reached varies from 3 - 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of infection, it may be necessary to increase the dosage and aim for higher trough levels.</p><p><u>Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic</u> <u>lymphocytic &nbsp;&nbsp;&nbsp;&nbsp; leukaemia, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whom &nbsp; prophylactic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have &nbsp;&nbsp;&nbsp;&nbsp; failed;</u> <u>hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple</u> <u>myeloma patients who have failed to respond to pneumococcal immunisation; congenital</u> <u>AIDS with recurrent bacterial infections:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 0.2-0.4 g/kg every three to four weeks.</p><p><u>Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell</u> <u>transplantation:</u></p><p>The recommended dose is 0.2-0.4 g/kg every three to four weeks. The trough levels should be maintained above 5g/l.</p><p><u>Primary immune thrombocytopenia:</u></p><p>There are two alternative treatment schedules:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.8-1g/kg given on day one; this dose may be repeated once within 3 days &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4 g/kg given daily for two to five days.</p><p>The treatment can be repeated if relapse occurs.</p><p><u>Guillain Barr&eacute; syndrome:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4 g/kg/day over 5 days.</p><p><u>Kawasaki Disease:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.6-2.0 g/kg should be administered in divided doses over two to five days or 2.0 g/kg as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.</p><p>The dosage recommendations are summarised in the following table:</p><table border="0" cellspacing="0" cellpadding="0" style="width:543px"><tbody><tr><td style="vertical-align:top"><p>Indication</p></td><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Frequency of injections</p></td></tr><tr><td style="vertical-align:top"><p>Replacement therapy in primary immunodeficiency</p><p>Replacement therapy in secondary immunodeficiency</p><p>Congenital AIDS</p><p>Hypogammaglobulinaemia</p><p>(&lt; 4 g/l) in patients after allogeneic haematopoietic stem cell transplantation</p></td><td style="vertical-align:top"><p><strong>- </strong>Starting dose:</p><p>0.4 - 0.8 g/kg <strong>- </strong>Thereafter:</p><p>0.2 - 0.8 g/kg</p><p>0.2 - 0.4 g/kg</p><p>0.2 &ndash; 0.4 g/kg</p><p>0.2 &ndash; 0.4 g/kg</p></td><td style="vertical-align:bottom"><p>every 3 - 4 weeks to obtain IgG trough level of at least 5-6 g/l</p><p>every 3 - 4 weeks to obtain IgG trough level of at least 5-6 g/l</p><p>every 3 - 4 weeks every 3 - 4 weeks to obtain IgG trough level above 5g/l.</p></td></tr><tr><td style="vertical-align:top"><p>Immunomodulation:</p><p>Primary immune thrombocytopenia</p></td><td style="vertical-align:bottom"><p>0.8 &ndash; 1.0 g/kg or</p><p>0.4 g/kg/d</p></td><td style="vertical-align:bottom"><p>on day 1, possibly repeated once within 3 days for 2-5 days</p></td></tr><tr><td><p>Guillain Barr&eacute; syndrome</p></td><td><p>0.4 g/kg/d</p></td><td><p>for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>Kawasaki disease</p></td><td style="vertical-align:bottom"><p>1.6 &ndash; 2 g/kg or</p></td><td><p>in divided doses over 2 - 5 days in association with acetylsalicylic acid</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2 g/kg</p></td><td style="vertical-align:top"><p>in one dose in association with acetylsalicylic acid</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.</p><p>Method of administration</p><p>For intravenous use.</p><p>OCTAGAM should be infused intravenously at an initial rate of 1 ml/kg/hour for 30 minutes. If well tolerated, the rate of administration may gradually be increased to a maximum of 5 ml/kg/hour.</p><p>Filtration of OCTAGAM is not required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to any of the components of OCTAGAM.
Hypersensitivity to homologous immunoglobulins, especially in the very rare cases of IgA deficiency when the patient has antibodies against IgA.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>should be brought to room or body temperature before use.</p><p>The solution should be clear or slightly opalescent.</p><p>Do not use solutions that are cloudy or have deposits.</p><p>Certain severe adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under &ldquo;4.2.2 Method of administration&quot; must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.</p><p>Certain adverse reactions may occur more frequently:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of high rate of infusion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with hypo- or agammaglobulinaemia, with or without IgA deficiency</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion</p><p>True hypersensitivity reactions are rare. They can occur in very seldom cases of IgA deficiency with anti-IgA antibodies.</p><p>Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.</p><p>Potential complications can often be avoided by ensuring:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that patients are not sensitive to human normal immunoglobulin by initially injecting the product slowly (1 ml/kg/hour);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that patients are carefully monitored for any symptoms throughout the infusion period; in particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product to OCTAGAM or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.</p><p>There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, stroke, pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients. Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with preexisting risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity).</p><p>Cases of acute renal failure have been reported in patients receiving IVIg therapy. In most cases, risk factors have been identified (such as pre-existing renal insufficiency, diabetes</p><p>mellitus, age over 65, hypovolemia, overweight or concomitant nephrotoxic medicinal products).</p><p>In case of renal impairment, IVIg discontinuation should be considered. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products that do not contain sucrose may be considered.</p><p>OCTAGAM contains maltose, a disaccharide sugar, which is derived from corn. Anaphylactoid / anaphylactic reactions have been reported in association with infusion of other maltose / corn starch related products. Patients known to have corn allergies should either avoid using OCTAGAM or be closely observed for signs and symptoms of acute hypersensitivity reactions.</p><p>In patients at risk for acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.</p><p>In all patients, IVIg administration requires:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adequate hydration prior to the infusion of IVIg</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of urine output</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of serum creatinine levels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoidance of concomitant use of loop diuretics</p><p>In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the side effects.</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as HIV, HBV and</p><p>HCV.</p><p>The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.</p><p>There is a reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.</p><p>It is strongly recommended that every time that OCTAGAM is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The infusion line may be flushed before and after administration of OCTAGAM with either normal saline or 5% dextrose in water.</p><p><u>Live attenuated vaccines</u></p><p>Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore patients receiving measles vaccine should have their antibody status checked.</p><p><u>Interference with serological testing</u></p><p>After injection of immunoglobulin the transitory rise of various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing.</p><p>Passive transmission of antibodies to erythrocyte antigens, e. g. A, B, D may interfere with some serological tests for red cell allo-antibodies (e.g. Coombs test), reticulocyte count and haptoglobin.</p><p><u>Blood Glucose Testing</u></p><p>Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in OCTAGAM as glucose. This may result in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering OCTAGAM or other parenteral maltose- containing products, the measurement of blood glucose must be done with a glucose-specific method.</p><p>The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltosecontaining parenteral products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy on the foetus or the neonate are to be expected. Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects on ability to drive and use machines have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, various minor allergic and hypersensitivity type of reactions and headache, chills, back pain, chest pain, fever, cutaneous reactions, fatigue, hot flushes and nausea may occasionally occur. Reactions to intravenous immunoglobulins tend to be related to the dose and the rate of infusion.</p><table border="0" cellspacing="0" cellpadding="0" style="width:528px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA 8.1 Coded</strong></p></td><td style="vertical-align:top"><p><strong>Common <u>&ge;</u>1% - &lt;10%</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon <u>&ge;</u>0.1% - &lt;1%</strong></p></td><td style="vertical-align:top"><p><strong>Rare <u>&ge;</u>0.01% - &lt;0.1%</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare &lt; 0.01%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>leukopenia;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic shock; anaphylactic reaction; anaphylactoid reaction; angioneurotic oedema; face oedema</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic and nutritional disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fluid overload</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>agitation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cerebrovascular accident; meningitis aseptic;</p><p>migraine; dizziness; paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myocardial infarction; tachycardia; palpitations; cyanosis</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension</p></td><td style="vertical-align:top"><p>thrombosis; peripheral circulatory failure; hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>respiratory failure; pulmonary embolism; pulmonary oedema; bronchospasm; dyspnoea; cough</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vomiting; diarrhoea; abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eczema;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urticaria; rash; rash erythematous;</p><p>dermatitis; pruritus; alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arthralgia; myalgia pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure acute</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>fatigue; injection site reaction</p></td><td style="vertical-align:top"><p>pyrexia; chills; chest pain hot flush</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>flushing; hyperhidrosis; malaise</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic enzymes increased</p></td><td style="vertical-align:top"><p>blood glucose false positive</p></td></tr></tbody></table><p>Rarely OCTAGAM may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.</p><p>Standard measures are taken to prevent infections resulting from the use of medicinal products prepared from human blood or plasma. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. For safety with respect to transmissible agents, see 4.4.</p><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340 o Toll free phone: 8002490000 o E-mail: <u>npc.drug@sfda.gov.sa </u>o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with renal impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration</p><p>ATC-Code: J06 BA02</p><p>Human normal immunoglobulin contains mainly &ge; 95 % immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.</p><p>IgA content is  0.2 mg/ml.</p><p>Opsonisation and neutralisation of microbes and toxins has been documented.</p><p>OCTAGAM contains all the IgG activities which are present in the normal population.</p><p>It is prepared from pooled plasma from not fewer than 3500 donations.</p><p>OCTAGAM has a distribution of IgG-subclasses:</p><p>IgG<sub>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>ca. 60 %</p><p>IgG<sub>2 </sub>ca. 32 % IgG<sub>3 </sub>ca.&nbsp;&nbsp; 7 % IgG<sub>4 </sub>ca.&nbsp;&nbsp; 1 %</p><p>which are closely proportional to that in native human plasma. Adequate doses of this medicinal product may restore abnormally low IgG level to the normal range.</p><p>The mechanism of action in idiopathic thrombocytopenic purpura is not fully elucidated.</p><p>The IgG-molecules have not been chemically or enzymatically modified. The antibody activities are fully functional. OCTAGAM contains  3.0 % polymers. Monomer and dimer is  90 %.</p><p>OCTAGAM has a broad spectrum of antibodies against various infectious agents (e.g. antibody titer for streptococcus and hepatitis B-antigen is established at 3 times the initial plasma pool), corresponding to those pathogens endemic in Europe and North America.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human normal immunoglobulin is immediately and completely bioavailable in the patient&rsquo;s circulation after intravenous administration. It is distributed relatively rapidly between plasma and extravascular fluid, after 3-5 days equilibrium is reached between the intra- and extravascular compartments.</p><p>Human normal immunoglobulin has a half life of about 40 days. This half-life may vary from patient to patient, in particular in primary immunodeficiency.</p><p>IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunoglobulins are normal constituents of the human body. In animals, acute toxicity testing is of no relevance. Repeated dose toxicity testing and embryo-foetal toxicity studies are impracticable. Effects of the product on the immune system of the newborn have not been studied.</p><p>Virus inactivation by the SD method is carried out with TNBP and Octoxynol (Triton X100). The maximum permitted amounts in the final product are  1 &micro;g/ml TNBP and</p><p> 5 &micro;g/ml Octoxynol. In the doses in which OCTAGAM is administered, these substances have been found to have no toxic effects in animal tests concerning acute and chronic toxicity, teratogenicity and embryotoxicity.</p><p>Since clinical experience provides no hint for tumorigenic or mutagenic effects of immunoglobulins, experimental studies, particularly in heterologous species, are not considered necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maltose&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;100 mg/ml<br />Octoxynol (Triton X-100)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &le; 5 &mu;g/ml<br />TNBP (Tri-n-butyl-phosphate)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&le; 1 &mu;g/ml<br />Water for injections&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ad 1 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OCTAGAM must not be mixed with other medicinal drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years at +2°C to +25°C
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product should be stored and transported at +2&deg;C to +25&deg;C. Do not freeze. Keep container in the outer carton in order to protect from light. Do not use after the expiry date.</p><p>Because of the possibility of bacterial contamination, any remaining contents must be discarded.</p><p>Keep out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><em>Package size</em></p></td><td><p><em>Contents</em></p></td><td><p><em>Container</em></p></td></tr><tr><td><p>OCTAGAM 1 g</p></td><td><p>20 ml</p></td><td><p>30 ml injection vial</p></td></tr><tr><td><p>OCTAGAM 2.5 g</p></td><td><p>50 ml</p></td><td><p>70 ml infusion bottle</p></td></tr><tr><td><p>OCTAGAM 5 g</p></td><td><p>100 ml</p></td><td><p>100 ml infusion bottle</p></td></tr><tr><td><p>OCTAGAM 10 g</p></td><td><p>200 ml</p></td><td><p>200 ml infusion bottle</p></td></tr></tbody></table><p>The primary container is made of Ph. Eur. type II glass closed with bromobutyl rubber stopper.<br />Components used in the packaging of OCTAGAM are latex-free.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.1	Marketing authorisation holder
Octapharma Pharmazeutika Produktionsges.m.b.H. Oberlaaer Strasse 235, A-1100 Vienna, Austria
7.2	Manufacturer
Octapharma Pharmazeutika Produktionsges.m.b.H. Oberlaaer Strasse 235, A-1100 Vienna, Austria
Octapharma S.A.S.
70-72 rue de Marèchal Foch, BP 33, F-67380 Lingolsheim, France
Octapharma AB
SE-112 75 Stockholm, Sweden
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>